Low-dose renin inhibitor and low-dose AT1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes

Abstract

We studied the effects of extremely low-dose human renin inhibition (aliskiren) with low angiotensin II receptor blockade (losartan) in a novel double-transgenic rat model harbouring both human renin and angiotensinogen genes. We found that low-dose aliskiren and low-dose losartan effectively reduced mortality and target-organ damage with minimal, non-significant, effects on blood pressure (BP). Our data suggest that renin-angiotensin system (RAS) inhibition ameliorates target-organ damage in an Ang II-driven model of hypertension. Direct renin inhibition is equally efficacious in this regard. Our study does not fully answer the question of BP-lowering versus RAS inhibition. This question is important and was at least partially addressed with our low-dose model.

Keywords

angiotensin II renin inhibitor inflammation albuminuria cardiac damage

Get full access to this article

View all access options for this article.

References

Ganten D. , Wagner J. , Zeh K. et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA 1992;89:7806-10.

Mervaala E. , Muller DN , Schmidt F. et al. Blood pressureindependent effects in rats with human renin and angiotensinogen genes. Hypertension 2000;35:587-94.

Muller DN , Shagdarsuren E. , Park JK et al. Immunosuppressive treatment protects against angiotensin IIinduced renal damage. Am J Pathol 2002;161:1679-93.

Pilz B. , Shagdarsuren E. , Wellner M. et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76.

Shagdarsuren E. , Wellner M. , Braesen JH et al. Complement activation in angiotensin II-induced organ damage. Circ Res 2005;97:716-24.

Weir MR , Dzau VJ The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999;12:205S-213S.

Mervaala EMA , Muller DN , Schmidt F. et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 2000;35:587-94.

Bidani AK , Griffin KA Pathophysiology of hypertensive renal damage: implications for therapy . Hypertension 2004;44:595-601.

Ichihara A. , Hayashi M. , Kaneshiro Y. et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the `handle` region for nonproteolytic activation of prorenin. J Clin Invest 2004;114:1128-35.

10.

Nguyen G. , Delarue F. , Burckle C. et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-27.